A Clinical Profile of Hepatitis a Patients in Jakarta, Indonesia by Adiwinata, R. (Randy) et al.
Makara J. Health Res., 2017, 21(1): 1-5 
doi: 10.7454/msk.v21i1.4610 
April 2017 | Vol. 21 | No. 1 1
A Clinical Profile of Hepatitis A Patients in Jakarta, Indonesia 
 
Randy Adiwinata1, Andi Kristanto1, Timoteus Richard1, Daniel Edbert1, Frida Angelina2, Eppy3, 
Ifael Yerosias Mauleti4, Soroy Lardo5, Iman Firmansyah6, Rika Bur7, Titos Ahimsa8,  
Erni Juwita Nelwan9* 
 
1. Faculty of Medicine, Universitas Katolik Indonesia Atmajaya, Jakarta 14440, Indonesia 
2. Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia 
3. Department of Internal Medicine, Persahabatan Hospital, Jakarta 13230, Indonesia 
4. Department of Internal Medicine, Fatmawati Hospital, Jakarta 12430, Indonesia 
5. Department of Internal Medicine, Gatot Soebroto Central Army Hospital, Jakarta 10410, Indonesia 
6. Department of Internal Medicine, Sulianti Saroso Hospital, Jakarta 14340, Indonesia 
7. Department of Internal Medicine, Anak Bunda Harapan Kita Hospital, Jakarta 11420, Indonesia 
8. Department of Internal Medicine, Cengkareng Hospital, Jakarta 11730, Indonesia 
9. Division of Tropical and Infectious Disease, Department of Internal Medicine, Universitas Indonesia,  
Jakarta 10430, Indonesia 
 
*E-mail: ejnelwan@yahoo.com 
 
 
Abstract 
 
Background: To determine the incidence of hepatitis A infections and the clinical profiles of adult patients admitted to 
public hospitals in Jakarta, Indonesia. Methods: This was a cross-sectional study that utilised consecutive secondary 
data from internal medicine wards of seven public hospitals in Jakarta between 2011 and 2013. Eligibility criteria 
included patients over the age of 18 years and an ICD-10 diagnosis code of B15, acute hepatitis A. Case proportion was 
reported per 1000 people by dividing incidence per year to total in-ward patients. Clinical profiles were reported 
descriptively. Laboratory results were compared and categorised into groups of patients aged below and above 25 years 
old. Results: Data revealed that hospitalisations of patients with hepatitis A had decreased from 2011 to 2013. 289 
patients were studied, the majority were young adults (18-25 years old) and their common chief complaints were nausea 
(36%), fever (24%), and jaundice (21%). Higher bilirubin levels were seen in older patients. There were 13 patients 
coinfected with hepatitis B, one patient coinfected with hepatitis C, and one patient coinfected with HIV. Conclusions: 
The proportion of hepatitis A infection amongst adults admitted to public hospitals in Jakarta was low and had 
decreased during the study period. Most of the patients reported classical clinical manifestations. This study found that 
the targeted age group may benefit from receiving routine hepatitis A vaccinations. 
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Introduction 
 
Hepatitis A is an acute liver disease caused by the hepatitis 
A virus (HAV), a ribonucleic acid picornavirus. The 
HAV is transmitted through the faecal-oral route, either 
from person to person or through contaminated food or 
water. It is strongly related to personal hygiene and 
lower standards of living.1,2 In the last few years, many 
developing countries with a high endemicity of hepatitis 
A infections have reported a decreased incidence of the 
disease. These findings were related to improvements in 
standards of living, sanitation, and socio-economic 
conditions.3 Between 1978 and 1981 Indonesia reported 
98% seroprevalence of HAV in persons aged 15 to 19 
years old. A comparison of data from 1994 to 1996 
showed that among children aged 10 to 19 years there 
was 97% seroprevalence of HAV in those living in rural 
areas versus only 35% seroprevalence in 15 to 19 year 
olds residing in urban areas.4 Urban populations 
experience a higher incidence of adult patients with 
symptomatic HAV which can increase mortality and 
morbidity rates.4,5 These conditions have encouraged 
many Asian countries to reassess and reevaluate their 
hepatitis A vaccination policies. 
 
In Indonesia the HAV infection occurs mostly in 
children.4 30% of children aged below 6 are infected by 
the HAV and usually develop non-specific symptoms or 
are asymptomatic. However, adults infected with the 
HAV will develop more classic symptoms such as 
jaundice and whilst the majority of cases do not require 
hospitalisation, disease severity will increase with a 
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patient’s age.6 Hospitalisation rates can be used as an 
indicator for disease severity and can affect a patient’s 
productivity, social and economical outcome.7 There is 
no specific treatment available for hepatitis A that can 
shorten the duration of illness.6,8 Indonesia experiences a 
moderate degree of endemicity for the HAV and currently 
has no recommendations for routine vaccinations.3 Limited 
data is available regarding hepatitis A prevalence in 
Indonesia and as such, this study aims to determine the 
proportion of hepatitis A infection, establish a clinical 
profile, and provide a comparison of disease severity 
between age groups that were admitted to public hospitals 
in Jakarta between 2011 and 2013.  
 
Methods 
 
This cross-sectional study was carried out in seven 
public hospitals in Jakarta, which represent each district 
of Jakarta using a convenience sampling methods. These 
hospitals were Cipto Mangunkusumo Hospital (Central 
Jakarta), Gatot Soebroto Central Army Hospital (Central 
Jakarta), Fatmawati Hospital (South Jakarta), Cengkareng 
Hospital (West Jakarta), Anak Bunda Harapan Kita Hospital 
(West Jakarta), Sulianti Saroso Hospital (North Jakarta), 
and Persahabatan Hospital (East Jakarta). All data was 
collected consecutively from each patient’s medical 
records. Ethical approval was obtained from the Ethical 
Board of the Universitas Indonesia. 
 
Study subjects. Medical records of all patients older 
than 18 years, who tested positive to the IgM anti-HAV, 
were reviewed. Clinical information obtained from 
these medical records was used to answer a structured 
questionnaire, including information about sex, age, 
length of hospitalisation, symptoms, and the onset of 
disease. Data on laboratory results such as AST, ALT, 
total bilirubin, and direct bilirubin levels at admission, 
as well as CD4 cell counts and IgM anti-HAV, HbsAg, 
anti-HCV, and HIV status were recorded. 
 
Statistical analysis. The WHO’s classification for demo- 
graphic, social, and related economic data was used to 
compare our the age groups.9 Additionally, possible 
relationships between hepatitis A disease severity and 
increasing age were explored. Independent sample T-
tests and Mann-Whitney tests were used to determine 
differences between the two groups. Statistical analysis 
was carried out using the Statistical Program for Social 
Sciences (ν 20.0; SPSS Inc., Chicago, IL, USA). The 
two-tailed value of p < 0.05 was considered statistically 
significant. 
 
Results 
 
Between 2011 and 2013 there was a total of 289 cases 
of laboratory confirmed, acute hepatitis A admitted to 7 
public hospitals in Jakarta. To break this down further, 
there were 105 confirmed cases in 2011, 117 cases in 
2012, and 67 cases in 2013. 
 
Table 1.  Clinical Characteristics of Patients with Acute Hepatitis a who were admitted to 7 Public Hospitals in Jakarta 
between 2011 and 2013 
 
Variables 2011 (n = 105) 2012 (n = 117) 2013 (n = 67) 
Total in-ward patients  16,868 23,571 21,991 
Rates of Hospitalisation 6.22/1000# 4.96/1000 3.04/1000 
Median age, (IQR) 24  (9) 25  (10) 26  (14) 
Male (%) 73 (69.5) 75 (64.1) 35 (52.2)
Median onset, days (IQR) 4 (4) 4 (4) 5 (4) 
Median length of stay, days, (IQR) 6 (4.75) 6 (5) 7 (3) 
Hepatitis B (%)    
    Positive  6 (5.7) 3 (2.6) 4 (5.9) 
    Negative 78 (74.3) 77 (65.8) 49 (73.1) 
    Not Tested  21 (20) 37 (31.6) 14 (21) 
Hepatitis C (%)    
    Positive 1 (1.0) 0 (0.0) 0 (0.0) 
    Negative 66 (62.9) 72 (61.5) 44 (65.7) 
    Not tested 38 (36.2) 45 (38.5) 23 (34.3) 
HIV (%)    
    Positive 0 (0.0) 1 (0.9) 0 (0.0) 
    Not tested 105 (100) 116 (99.1) 67 (100) 
Lab findings, median (IQR)    
    AST (U/L) 546 (725) 566 (838) 342 (629) 
    ALT (U/L) 1,083.5 (963) 1,192 (1202) 768 (976) 
    Total Bilirubin (mg/dL) 5.8 (4.1)* 6.2 (4.0)** 6.7 (8.3)*** 
    Direct Bilirubin (mg/dL) 4.3 (3.5)* 4.7 (3.6)** 5.4 (5.9)*** 
  #No data available from Gatot Soebroto Central Army Hospital in 2011 
*Data valid for 93 subjects 
** Data valid for 102 subjects 
*** Data valid for 60 subjects 
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Among 217 patients with a positive IgM anti-HAV 
whom screened for Hepatitis B, we found 13 patients 
tested positive to HbsAg, thus the rate of hepatitis B 
coinfection was 4.5%. Additionally, 183 patients with 
positive IgM anti-HAV were screened for hepatitic C, 
and only 1 patient tested positive (0.3%). None of the 
patients in the study sample tested positive for a triple 
infection. Only 1 patient was HIV seropositive with a 
CD4 level of 789/µL, and was being treated with 
antiretrovirals. There were no cases of hepatitis leading 
to death included in this study. 
 
The median age of  the sample population was 25 years 
and the ratio of male to female subjects was 1.7:1. The 
most commonly affected age group was those aged 18 
to 25 years (n = 162), followed by the 25 to 35 years age 
group (n = 78), the 36 to 45 years age group (n = 32), 
the 46 to 55 years age group (n = 13), and finally 
patients over 55 years (n = 4).  
The demographics and laboratory findings of all 289 
subjects is summarised in Table 1. 
 
The most common chief complaint of all 289 hospitalised 
subjects was nausea (36%), followed by fever (24%), and 
jaundice (21%). A summary of symptoms as reported 
by patients is shown in Figure 1. 
 
Comparison of laboratory parameters, using the Mann-
Whitney test, between patients aged below and above 
25 years showed that there was a significant difference 
for direct bilirubin, 4.5 mg/dL versus 5.4 mg/dL (p < 
0.05), and total bilirubin, 5.8 mg/dL versus 6.8 mg/dL 
(p < 0.05) respectively. There was no significant 
differences between other parameters such as AST, 
ALT, and indirect bilirubin (Table 2 & 3). 
 
 
 
  
Figure 1. Common Symptoms Experienced by Patients with Acute Hepatitis A (n = 289). RUQ: Right Upper Quadrant 
 
 
Table 2. Comparison of AST and ALT Values Between Two Age Groups 
 
Variable Age < 25 yo (n = 140) Age ≥ 25 yo (n = 146) p value  Median (IQR) Median (IQR) 
AST 536 U/L (698.0) 476 U/L (763.5) 0.836 
ALT 1,039 U/L (1008.5) 1,012 U/L (1242.3) 0.943 
 
 
Table 3. Comparison of Bilirubin Levels between Two Age Groups 
 
Variable Age < 25 y.o. (n = 123) Age ≥ 25 y.o. (n = 132) p value  Median (IQR) Median (IQR) 
Direct Bilirubin 4.5 mg/dL (3.1) 5.4 mg/dL (5.6) 0.029 
Indirect 
Bilirubin 1.3 mg/dL (0.8)  1.4 mg/dL (1.7) 0.545 
Total Bilirubin 5.8 mg/dL (3.6) 6.8 mg/dL (6.4) 0.032 
n=55
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n=275 
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Discussion 
 
National reports include acute hepatitis A as a leading 
cause of hospitalisation in Indonesia (39.8-68.3%), 
however the incidence of infection has steadily decreased 
in the last 3 years, in the 7 public hospitals in Jakarta that 
were studied.8 This finding is in contrast with a report 
from Korea’s Centre for Disease Control and Prevention, 
which showed an exponentially increasing number of 
symptomatic HAV infections since 2006.10 However, a 
recent report from the United States of America showed 
similar findings of decreased hospitalisation rates, from 
0.72 cases per 100,000 to 0.29 cases per 100,000.7 
Declining incidence rates of hepatitis A in many 
developing countries has lead to a changing level of 
endemicity.3 Indonesia’s close neighbour, Singapore, 
has also seen a significant reduction in the incidence of 
hepatitis A from 1.8 cases per 100,000 in 1989 to 0.7 
per 100,000 in 2009.1 As such, the decreased incidence 
of acute hepatitis A in 7 of Jakarta’s public hospitals in 
the past three years is not sufficient to determine the 
endemicity status of the country, and data on the sero-
prevalence of anti-IgG HAV in all age groups are needed. 
 
Patients with acute hepatitis are not routinely screened 
for complete seromarkers of hepatitis due to the costs 
involved. This study found very few cases of coinfection 
with other hepatitis or blood borne viruses. A report 
from North India (2011-2012) showed that among 267 
hepatitis virus cases, there were 34 cases of hepatitis 
coinfection with 6 cases of HAV-HBV coinfection.11 
Similarly, no routine tests were conducted to determine 
HIV status amongst patients with acute hepatitis. A 
study in Poland in 2008 to 2009, found that out of 40 
homosexual patients with the HAV, 6 patients were 
positive for HIV.12 Patients with HIV have a higher risk 
of contracting the HAV due to high risk behaviours 
such as practicing male to male anal sex, and higher 
incidences have also been reported amongst men in 
Europe who identify as an injecting drug user or 
homosexual.12,13 Generally speaking, the ratio of hepatitis 
A cases between men and women is 1.7:1.1,6 Limited 
information on subject’s history of intravenous drug use 
was collected during this study. 
 
There is a wide spectrum of clinical manifestations of 
hepatitis A, from asymptomatic to fulminant. The severity 
of hepatitis A depends on the age of the person and 
symptoms typically include malaise, anorexia, abdominal 
discomfort, vomiting, fatigue, diarrhea, and less commonly 
fever, headaches, arthralgia, and myalgia. The classic 
manifestations are elevated levels of liver enzymes, the 
appearance of dark urine, dark-coloured stools, and 
jaundice.14 These clinical manifestations are due to the host 
immunologic response against the viral infection, which 
can induce acute liver injury. Intrahepatic inflammation 
impairs transport of conjugated bilirubin, leading to an 
accumulation of bilirubin in the skin and sclera, which 
causes jaundice.15 The most common presenting symptoms 
found in this study were nausea (36%), followed by 
fever (24%), and jaundice (21%). 
 
The majority of subjects in this study (56%) were aged 
between 18 and 25 years old, this age group is pre-
dominantly consisted of workers or students presented 
with the classical features of acute hepatitis A infection. 
Hepatitis A does not usually result in long-term 
complications in this age group, however it can cause 
disadvantage to their productivity, social circles, and the 
economy. The average length of hospitalisation in the 
sample group was 6 days and there are no specific 
therapies available to shorten the length of illness.8 The 
only effective prevention of hepatitis A is via vaccination, 
with the vaccine having a 94-95% protective efficacy 
and predicted protection up to 45 years.14 Vaccination 
has been proven effective at maintaining a lower risk of 
infection as per studies conducted on toddlers in Israel.16 
Therefore, WHO recommends that vaccines should be 
administered universally in low endemic countries like 
America, Australia, and Northern and Western Europe. 
Additionally, they advise that should be targeted to 
people in high risk groups, such as men who have sex 
with men, tourists travelling to highly endemic countries, 
those requiring life-long treatments with blood products, 
people living in hepatitis A outbreak communities, people 
who are at a high risk of contracting infections, or those 
with chronic liver disease. WHO recommends national 
vaccination programs for children older than 1 year old, 
based on the changes in the incidence of acute hepatitis 
A, changes in endemicity from high to intermediate, and 
the vaccines cost effectiveness.14  
 
Results from our laboratory testing showed a marked 
increase of ALT compared to AST and elevated levels 
of direct bilirubin, these are similar to the results of 
other studies.17 Lee et al. found the mean levels of ALT 
was 3108 U/L in Korean people with acute Hepatitis A, 
which is higher than the mean levels of ALT found in 
our study population. This difference may be due to the 
older age distribution of the Korean sample group.18 As 
per the United Nations recommendations, the sample 
population was divided into two groups based on the 
median age, for ease of classification.9 Our results also 
found that levels of total bilirubin and direct bilirubin 
were significantly higher in the over 25 age group. 
Higher levels of bilirubin in patients aged over 25 reflects 
that the hepatitis A virus tends to be more symptomatic 
in older patients. Differences of transaminase levels 
between the two age groups failed to show any significant 
impact.  
 
Hepatitis A vaccination is not currently mandatory in 
Indonesia; however certain countries in Asia are 
considering universal hepatitis A vaccinations. This 
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study is representative of the current prevalence of 
Hepatitis A in Jakarta. With the capital of Indonesia being 
an important destination for both work and tourism in 
Asia, further research regarding the national seroprevalence 
to determine endemicity levels and the cost effectiveness 
of providing routine hepatitis A vaccines are needed. 
 
Conclusions  
 
Low hospitalisation rates of patients with the hepatitis A 
infection in Jakarta was represented by young productive 
age. Routine Hepatitis A vaccinations in young adults, 
as a part of the national immunisation program, is 
beneficial as it is highly protective, it increases productivity 
by reducing absenteeism from work, and decreases the 
health cost of hepatitis A in Indonesia. 
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